Literature DB >> 9578917

Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.

B A Cohen1, P A Greenberger, S Saini.   

Abstract

We report a case of a patient treated for relapsing multiple sclerosis (MS) with interferon beta-1b who developed a severe vasculitic-like skin reaction 9 months after initiation of interferon therapy. Prompt discontinuation of interferon beta-1b and institution of corticosteroid therapy was associated with complete resolution of the cutaneous lesions. Other potential causative agents were excluded by penicillin skin sensitivity testing or continuing use in the absence of adverse reactions. We conclude that a vasculitic-like cutaneous reaction to interferon beta-1b may occur long after institution of therapy in some MS patients. We review other case reports of severe cutaneous reactions associated with interferon beta-1b therapy in MS patients that suggest that susceptibility cofactors may be important elements in the occurrence of these reactions, and consider whether other medications commonly used in MS patients could have such a role.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578917     DOI: 10.2500/108854188778607200

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  2 in total

Review 1.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 2.  Management of pain in multiple sclerosis: a pharmacological approach.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.